Journey Medical Corporation (DERM)
NASDAQ: DERMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DERM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $93.16M
- EPS (TTM)
- -$0.18
- Dividend yield
- None
- 52-week range
- 3.21 – 9.56
- Day range
- 3.21 – 3.57
- Volume / Avg
- 244.74K / 190.39K
- Beta
- —
- Shares outstanding
- 22.23M
52-week range
DERM stock today
On Nov 20, DERM ended the session at $3.30, shedding $0.25 (7.04%), versus the S&P 500's 3.70% decline. At this level, DERM sits near the bottom of its 52-week range of $3.21 to $9.56: 65.5% below the high, set on Jan 23, 2026 and 2.8% above the low. DERM is down 57.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.8%.
Journey Medical has posted a net loss over the last twelve months (EPS of -$0.18), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Journey Medical
Company profileJourney Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Claude Maraoui
- Headquarters
- Scottsdale, AZ
- Employees
- 58
- IPO year
- 2021
- Website
- journeymedicalcorp.com
Financial highlights
Full financialsIn fiscal 2025, Journey Medical generated $61.9 million in revenue, up 10.2% from fiscal 2024. Journey Medical reported a net loss of $11.4 million, compared with a loss of $14.7 million a year earlier. Gross margin was 66.2% (up from 62.8%) and operating margin -13.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $61.86M | $56.13M | $79.18M | $73.67M | $63.13M |
| Growth | +10.20% | -29.11% | +7.48% | +16.69% | +41.78% |
| Net income | $-11.43M | $-14.67M | $-3.85M | $-29.63M | $-43.99M |
| EPS (diluted) | $-0.47 | $-0.72 | $-0.21 | $-1.69 | $-4.32 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$12.75+286.36%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.09 vs $-0.03
- Surprise
- -200.00%
DERM news
All DERM news- Journey Medical (DERM) Q3 2026 Earnings Call TranscriptNasdaq
- Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireDERM, FBIO
- Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireDERM, FBIO
Journey Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs DERM |
| CATXPerspective Therapeutics Inc. | 0.7538 | -3.85% | $91.03M | vs DERM |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs DERM |
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs DERM |
| NTHINeOnc Technologies Holdings Inc. | 3.15 | -9.48% | $90.88M | vs DERM |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs DERM |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs DERM |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs DERM |
Indexes, lists and sector
Journey Medical stock FAQ
What is Journey Medical's stock price today?
DERM last traded at $3.30 as of Nov 20, 4:00 PM EST, down 7.04% on the day. Prices are delayed at least 15 minutes.
Who is Journey Medical's CEO?
Mr. Claude Maraoui is the chief executive officer of Journey Medical Corporation, which has about 58 employees.
What is the DERM 52-week high?
The 52-week high for DERM is $9.56 and the 52-week low is $3.21. The stock is currently 65.5% below its high.